Christopher Henson, MD
Internal Medicine · Evans, GANPI 1871688697
Payments from drug & device makers
Across 769 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AbbVie$3K
- GSK$2K
- AstraZeneca$2K
- Lilly USA, LLC$2K
- Amgen$826
- plus $5K from 29 others
What the payments were for
- Speaking & faculty fees$1,1507%
- Food & beverage$15,91993%
- Education$610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 177 | $3,347 |
| AbbVie(2 entities) | 114 | $3,076 |
| GSK | 92 | $2,145 |
| AstraZeneca | 60 | $1,686 |
| Lilly USA, LLC | 85 | $1,512 |
| Amgen | 28 | $826 |
| Boehringer Ingelheim | 43 | $823 |
| Bayer | 22 | $615 |
| Abbott | 29 | $555 |
| Pfizer | 28 | $524 |
| Johnson & Johnson | 8 | $343 |
| Dexcom, Inc. | 12 | $226 |
| Sanofi-aventis U.S. LLC | 10 | $185 |
| Phathom Pharmaceuticals, Inc. | 6 | $184 |
| Exact Sciences | 10 | $139 |
| Mannkind Corporation | 1 | $125 |
| Corcept Therapeutics | 4 | $83 |
| Merck | 4 | $74 |
| E.r. Squibb & Sons, L.L.C. | 2 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Boston Scientific | 2 | $61 |
| Amarin Pharma, Inc. | 4 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Novartis | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,130 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $145,997 |
| JardianceEmpagliflozin | 124 | $141,293 |
| TrulicityDulaglutide | 103 | $138,926 |
| OzempicSemaglutide | 64 | $115,217 |
| FarxigaDapagliflozin Propanediol | 106 | $101,783 |
| RybelsusSemaglutide | 44 | $79,991 |
| EliquisApixaban | 60 | $75,664 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $62,942 |
| JanuviaSitagliptin Phosphate | 38 | $25,613 |
| XareltoRivaroxaban | 28 | $23,494 |
| LinzessLinaclotide | 24 | $16,192 |
| Humalog Kwikpen U-200Insulin Lispro | 19 | $11,145 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,889 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,329 |
| Rosuvastatin Calcium | 506 | $5,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,512 | $284,923210 claims |
| Novo NordiskOzempic, Rybelsus | $3,347 | $195,208108 claims |
| Boehringer IngelheimJardiance | $823 | $141,293124 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $1,686 | $106,711118 claims |
| PfizerEliquis | $524 | $75,66460 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,145 | $69,27176 claims |
| MerckJanuvia | $74 | $25,61338 claims |
| Johnson & JohnsonXarelto | $343 | $23,49428 claims |
| AbbVieLinzess, Synthroid | $3,076 | $17,66646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Evans
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.